Advertisement


Ronald de Wit, MD, PhD, on Prostate Cancer: Results of the CARD Trial on Cabazitaxel, Abiraterone, and Enzalutamide

ESMO 2019 Congress

Advertisement

Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses study findings which showed that cabazitaxel improved radiographic progression-free survival as well as overall survival in patients with metastatic castration-resistant prostate cancer (Abstract LBA13).



Related Videos

Prostate Cancer

Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer

Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses results from a long-term follow-up of a cohort treated with docetaxel in the STAMPEDE randomized trial, confirming that the treatment showed benefit in patients with both high- and low-volume disease (Abstract 844O).

Gynecologic Cancers
Immunotherapy

Mansoor R. Mirza, MD, on Ovarian Cancer: Roundup of ESMO 2019 Top Abstracts

Mansoor R. Mirza, MD, of Copenhagen University Hospital, offers his perspective on three studies presented in the Presidential Symposium: the PRIMA/ENGOT-OV26/ GOG-3012 trial (niraparib for newly diagnosed advanced disease); the PAOLA-1/ENGOT-ov25 trial (olaparib plus bevacizumab maintenance therapy in newly diagnosed advanced disease); and the VELIA/COG-3005 study (integrating veliparib with front-line chemotherapy and maintenance therapy) (Abstracts LBA 1–4).

Lung Cancer

Laura Q.M. Chow, MD, on Metastatic NSCLC: Results of the ASCEND-7 Trial on Ceritinib

Laura Q.M. Chow, MD, of the University of Texas at Austin, Dell Medical School and LIVESTRONG Cancer Institutes, discusses phase II study findings that showed the ALK inhibitor ceritinib achieved durable intracranial response in patients with ALK-positive non–small cell lung cancer that has spread to the brain (Abstract 1478O).

Robin L. Jones, MD, MBBS, on Advanced Angiosarcoma: TAPPAS Trial of a Novel Monoclonal Antibody Plus Pazopanib

Robin L. Jones, MD, MBBS, of The Royal Marsden/Institute of Cancer Research, discusses the first phase III study in angiosarcoma, which showed no difference in outcome between pazopanib vs pazopanib plus the novel monoclonal antibody TRC105 (Abstract 1667O).

Prostate Cancer

Maha H.A. Hussain, MD, on Castration-Resistant Prostate Cancer: Olaparib/Enzalutamide/Abiraterone

Maha H.A. Hussain, MD, of Northwestern University Robert H. Lurie Comprehensive Cancer Center, discusses the phase III PROfound trial results on the efficacy of olaparib in men with metastatic castration-resistant prostate cancer whose tumors harbor alterations in DNA damage response genes and who had disease progression on prior hormone therapy (Abstract LBA12).

Advertisement

Advertisement




Advertisement